

ASX Release

Company update: including progress of Anti-Obesity Project pre-clinical studies & Japanese patent grant for GaRP

Highlights

- GaRP has been granted a Japanese patent for the product with the title of invention being “Gastrointestinal Health Composition.” This patent grant further consolidates the commercial proposition for the Company’s IP following the recently concluded GaRP-IBS (Irritable Bowel Syndrome) trial.
- The granted patent is valid in Japan for 20 years from 9 October 2020. This follows the previously announced similar grants for Hong Kong, Australia and the EU. The usual patenting processes are ongoing in further jurisdictions.
- The Anti-Obesity Project pre-clinical studies have progressed on schedule to the treatment challenge phase following the preparation of diet-induced obese mice.
- The Company received confirmation from AusIndustry on 08 July 2025 that its R&D Tax Incentive application has been Registered for the 2024-2025 income period.

ADELAIDE, 09 July 2025: Anatara Lifesciences (ASX: ANR or “the Company”), a developer of evidence-based, innovative products to address significant unmet need in human health, with a particular focus on conditions that involve the complexity of the gastrointestinal tract (GIT), is pleased to report the Company has received certification of the grant of a standard patent for the GaRP product under the invention title of “Gastrointestinal Health Composition” from the Japan Patent Office dated 20th June 2025 . The Japanese Patent Number 7700109 was granted by the Commissioner of the Japan Patent Office and has a term of 20 years from 9 October 2020 (therefore the expiry date is 9 October 2040).

This follows the Company receiving certification of a standard patent for the GaRP product under the invention title of “Gastrointestinal Health Composition” from the Government of Hong Kong dated 25th April 2025. Previously, the decision of a grant of a European patent from the European Patent Office (EPO) for the title and documents relating to its **Gastrointestinal ReProgramming** product (known as “GaRP”) took effect from the publication of the grant in the European Patent Bulletin 24/38 on the 18th September 2024.

A similar grant of an Australian patent was announced in January 2025. The commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is US\$8 billion in the US alone.¹

¹ <https://www.grandviewresearch.com/press-release/global-brain-health-supplements-market>



For personal use only

Progress of Anti-Obesity Project

The planned *in-vivo* pre-clinical experiments being conducted at the University of Newcastle have moved to a treatment challenge phase for one -arm of the intended project. This follows a period of preparing diet-induced obese mice for the study to observe weight loss control and maintenance in response to therapeutic inputs. The initial studies are anticipated to take approximately 6 months through to completion, depending on the observations of markers and weight control in the initial mice studies. The study may need further mice cohorts which will be determined on scientific outcomes and milestones and, if required, would extend the overall study by a further few months.

The anti-obesity project has been designed to develop an oral complimentary medication to assist weight reduction and sustaining weight control in conjunction with other contemporary treatments and approaches. Specifically, the product is being developed with the target of assisting the maintenance of weight loss and limiting rebound weight gain following cessation of contemporary weigh loss medications.

While the Company needs to protect the project at this early stage, the mechanism of action involves the stimulation of endogenous GLP-1. The Company will assess several compounds of interest (that have been sourced/manufactured) in the pre-clinical studies to determine the best candidate/s going forward. The candidate compounds selected have been shown to target the same physiological mechanism that is the focus of the Proof-of-Concept (POC). The dosage regimes have been predicted from published pre-clinical and clinical studies. The Company has allocated more than \$350,000 to the POC studies for the anti-obesity project and will determine further steps on the outcomes of these initial studies.

General Company update

While committed to the Anti-Obesity Project Proof of Concept studies, the Company continues to actively assess other opportunities and assets to add to the portfolio of projects that are consistent with addressing evidence-based unmet needs in human health.

Commercialisation discussions are being pursued for the GaRP product following the GaRP-IBS trial with headline results released 17 April 2025 and internal analyses on 16 May 2025. The trial was successful in achieving the primary endpoint of safety and secondary endpoints, including a statistically significant reduction in anxiety scores and the magnitude of improvement in the IBS-SSS (Irritable Bowel Syndrome-Symptom Severity Score). While the primary efficacy endpoint using the traditional, overall IBS-SSS did not meet statistical significance, internal analyses revealed statistically significant improvement in IBS symptoms of pain severity, pain frequency and abdominal distension in participants on the GaRP product compared to the placebo group. The Company is still of the view that the product has the potential for broad indications, including in the management of a healthy gut-brain axis.

The summarisation of the extensive GaRP project pre-clinical work, which used the internationally accepted IBD (Inflammatory Bowel Disease) model in mice, has been prioritised. The resultant intended publication is nearing completion and will enhance the understanding of the commercial possibilities for the GaRP product in gastrointestinal health. The Company is currently going through the usual responsibilities to close the GaRP-IBS trial and will formally write up for publication the GaRP-IBS trial results and conclusions.



The Company has received **confirmation of the registration of the R&D Tax Incentive application** for the 2024-2025 income period from AusIndustry on the 8th July 2025. This registration number will be included with the Company's income tax return for FY25 which is expected to be lodged within the next week.

About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's **Gastrointestinal ReProgramming** project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.

GaRP has the potential to be a disease-modifying treatment that aims to positively impact a substantial proportion of the population that suffer from the debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS). Due to the mechanism of action, GaRP is expected to be applicable to a wide range of indications in gastrointestinal health beyond IBS. The lack of efficacious IBS treatments underscores the clear unmet need for a health product that assists both the GIT lining as a barrier and the homeostasis of the microbiome. The commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is US\$8 billion in the USA.²

² <https://www.grandviewresearch.com/press-release/global-brain-health-supplements-market>



For personal use only

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com



For personal use only